南方财经记者伍素文 广州报道 2月24日，春节后开工第一天，广东连续第四年召开全省高质量发展大会，聚焦"制造业与服务业协同发 展"的主题，擂响拼开局拼经济的战鼓。来自政产学研各界代表亮家底、谈发展、表决心，共商高质量 发展的新路子。 大会提出，要在"制造强省"与"服务高地"相互成就中打开产业发展新天地。当前，新一轮科技革命和产 业变革加速突破，人工智能、生物制造、量子通信等前沿科技集群式爆发、多领域融合，对两业协同发 展提出紧迫要求，也提供了坚实支撑。传统工厂升级为智慧工厂，人工智能应用于疾病筛查、新药研 发，两业协同在生物医药领域已是显著趋势。 "目前，广药集团正通过现代化、科技化、数字化、国际化发展，力争'十五五'再造一个广药。大会提 出的'两业协同'新方向，恰恰切中了广药集团当前转型升级的机遇和挑战。"广药集团党委书记、董事 长李小军接受南方财经记者专访时说。 近年来，广药集团在科技创新的投入引人注目，从大力布局AI+制药到成立广药数科公司、牵头成立广 州市药械产品出口综合服务平台、与华为等科技巨头合作，一系列举措显示这家老牌药企在两业协同上 逐渐走出创新坚实的步伐。 南方财经：今年是广东连续第四年召开 ...

（原标题：广药集团新设资本公司，注册资本20亿） 企查查APP显示，近日，广州广药资本有限公司成立，注册资本20亿元，经营范围包含：以自有资金从 事投资活动；企业管理咨询。企查查股权穿透显示，该公司由广州医药集团有限公司全资持股。 ...

Business Progress - The company announced on February 11, 2026, that its subsidiary Tianxin Pharmaceutical and its branch Baiyunshan Pharmaceutical Factory have 24 products, including Cefuroxime Sodium for Injection, proposed for selection in the national drug procurement program. The total sales revenue for these products is projected to be 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% of revenue [1]. Subsidiary Development - On February 2 and 3, 2026, subsidiaries Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. received changes to their drug production licenses from the Guangdong Provincial Drug Administration, involving new production addresses or adjustments to production workshops aimed at improving production efficiency. However, this is expected to have no significant impact on current financials [2]. Product R&D Progress - On February 6, 2026, the company's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol Soft Capsules, which are used to treat calcium metabolism disorders [3]. Funding Movements - According to data disclosed on February 5, 2026, JPMorgan Chase increased its holdings in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, 2026, raising its ownership stake to 9.12%. Additionally, the company emphasized in its Q3 2025 report that it would continue to promote its dividend policy and capital operations, but the timing of related events should be confirmed with the latest announcements [4].

Core Viewpoint - Guangzhou Pharmaceutical Group Co., Ltd. has disclosed significant anti-corruption results in a recent annual report, highlighting the company's commitment to integrity and governance [1] Group 1: Anti-Corruption Measures - The report details 17 cases of corruption over the past year, with a total amount involved of approximately 170 million yuan [1] - Internal sources indicate that these cases have been communicated internally as warnings to staff [1] Group 2: Disciplinary Actions - In 2025, the disciplinary inspection and supervision agencies of Guangzhou Pharmaceutical Group and its subsidiaries investigated 30 individuals and imposed 42 party disciplinary and administrative penalties [1] - The 17 typical cases involved key personnel from major subsidiaries, including Zhongyi Pharmaceutical, Wanglaoji Pharmaceutical, Baiyunshan Pharmaceutical Factory, He Jigong Pharmaceutical Factory, and Huanhong Traditional Chinese Medicine [1]

重要提醒！！！为防失联，请"星标"我们！进入无冕财经公众号，点击右上角"..."，再" "，以便您及时接收每篇推送~ wumiancaijing.com 最热的泛财经新闻，都在这儿了。 2月12日，广药集团纪律检查委员会发布文件，集中通报去年17起严重违纪违法典型案例，其中包括此前备受关注的广药集团腐败"窝案"。 文件通报的17起要案中，涉及广药集团旗下中一药业、王老吉药业、白云山制药总厂、何济公制药厂等多家核心子公司，涉案人职位上到董事长、总经 理、副总经理、部门总监、经理等各级管理人员，下至保卫科科长。腐败行为集中在药品原材料及包装材料采购、药品代理经销、广告投放与业务承揽、 款项结算、职务晋升等关键领域，部分人员还存在依托他人职权谋取私利、销售假药等严重违法行为，涉案总金额超2亿元。 ▲图片来自网络。 资讯整理：小冕 编辑：陈涧 设计：岚昇 广药集团腐败窝案15人被判刑 涉案超2亿，李楚源处理结果未出 本文由无冕财经（wumiancaijing）整理发布 从已披露的结果看，已有15人因受贿罪或销售假药罪被判处有期徒刑。其中，王老吉药业是被点名频次最高的企业，违法违纪行为涉及广药集团和王老吉 药业广告与媒 ...

Company Developments - Baiyunshan announced that its subsidiary Tianxin Pharmaceutical and Baiyunshan Pharmaceutical Factory plan to participate in the national drug procurement for 24 products, with projected sales revenue of 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% [2] - Baiyunshan's subsidiaries, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., received production license changes from the Guangdong Provincial Drug Administration to enhance production capacity and efficiency, although no significant financial impact is expected in the current period [3] Product Development - Baiyunshan's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. has successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [4] Financial Movements - Morgan Stanley increased its stake in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, raising its ownership to 9.12% [5] - The company reported a year-on-year increase in revenue and net profit in its Q3 2025 report, emphasizing its ongoing dividend policy and capital operations [5]

上述通报显示，在此次通报的17人中，15人因受贿罪或销售假药罪被判处有期徒刑，刑期最高的为十二 年有期徒刑（方广宏），有2人涉嫌相关违法已受党纪政务处分，尚未提及判决结果。 责任编辑：何俊熹 2月12日消息，据报道，曾在2024年引发社会各界高度关注的广药集团反腐风波在近日终于有了结论。 中共广州医药集团有限公司（简称广药集团）纪律检查委员会近日公布了《穗药集纪2025》16号文件， 通报了广药集团2025年度一系列典型违纪违法案例，其中就包括2024年底引发社会各界高度关注的广药 集团腐败"窝案"，涉案人员包括广药集团原党委委员、副总经理张春波；广州王老吉药业股份有限公司 原总裁、董事长方广宏；广州王老吉药业股份有限公司营销中心常务副总经理赵敏等17人。 2月12日消息，据报道，曾在2024年引发社会各界高度关注的广药集团反腐风波在近日终于有了结论。 中共广州医药集团有限公司（简称广药集团）纪律检查委员会近日公布了《穗药集纪2025》16号文件， 通报了广药集团2025年度一系列典型违纪违法案例，其中就包括2024年底引发社会各界高度关注的广药 集团腐败"窝案"，涉案人员包括广药集团原党委委员、副总经理张春 ...

Group 1 - The core viewpoint of the article highlights the company's strategy to enhance the value of the Wanglaoji brand by expanding its distribution network and collaborating with major restaurant platforms [1] - The company is focusing on promoting bottled beverages and exploring new product lines, including original flavor herbal tea and various fruit-flavored juice products, to cultivate a second growth curve [1] - In the functional beverage segment, the company has launched Wanglaoji Flash Recharge Electrolyte Water, indicating its commitment to innovation in product offerings [1]

Core Viewpoint - The company announced its participation in the national organized procurement for the continuation of products from the first to eighth batches, aiming to secure contracts for 24 pharmaceutical products, including injectable Cefuroxime Sodium and Clindamycin Phosphate Injection [1] Group 1: Company Participation - The company’s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its branch, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., are involved in the procurement process [1] - The products targeted for procurement include Cefuroxime Sodium Injection, Clindamycin Phosphate Injection, Mebendazole Tablets, and Amoxicillin Granules among others [1] Group 2: Procurement Details - The procurement is based on the demand reported by medical institutions for each enterprise's products, with the selection price gradient determining the volume ratio [1] - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its injectable penicillin sodium, indicating successful compliance with the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The injectable penicillin sodium is approved in a dosage of 0.96g (1.6 million units) [1] - This medication is indicated for various infections caused by sensitive bacteria, including abscesses, bacteremia, pneumonia, and endocarditis [1]